GGrantIndex
Sort

48,018 grants matching immunotherapy

Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine

$367,441
University Of Washington · R01 · FY2003 · CA

Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy

$367,423
Zachary Scott Morris · University Of Wisconsin-Madison · P50 · FY2022 · CA

Mechanisms of cell regulation and transformation

$367,398
Titia De Lange · Rockefeller University · T32 · FY2008 · CA

Immune activation by cetuximab in head and neck cancer patients

$367,388
Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2011 · DE

Antigen specific T cell accumulation in the CNS

$367,370
Zsuzsanna Fabry · University Of Wisconsin-Madison · R56 · FY2008 · NS

The Role of IgE in Airway Inflammation

$367,369
Yang-Xin Fu · University Of Chicago · R01 · FY2006 · HL

Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling

$367,325
Seyed Javad Mirhassani Moghaddam · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

Assessing the determinants of durable protective immunity in SARS-CoV-2 infected human subjects

$367,304
Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2022 · AI

Clinical trial development in cancer vaccines

$367,265
Samir Khleif · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma

$367,259
Amaia Lujambio · Icahn School Of Medicine At Mount Sinai · R37 · FY2024 · CA

Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphoma

$367,186
Justin P. Kline · University Of Chicago · R01 · FY2023 · CA

Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphoma

$367,186
Justin P. Kline · University Of Chicago · R01 · FY2025 · CA

CD4-Independent Vaccinations for Pulmonary Infections

$367,184
Jay K Kolls · Lsu Health Sciences Center · P01 · FY2008 · HL

Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC

$367,178
Andrew B. Sharabi · University Of California, San Diego · R01 · FY2021 · DE

Targeting Metastatic Breast Cancer with Human Antibodies

$367,153
Scripps Research Institute · R01 · FY2005 · CA

Development of Chimeric Antigen Receptors Targeting Multiple Myeloma

$367,151
James Kochenderfer · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Clinical Scholars Biomedical Research Training Program

$367,150
Ping Chi · Sloan-Kettering Inst Can Research · T32 · FY2019 · CA

CAR NKT Cell Immunotherapy of Neuroblastoma

$367,144
Leonid S Metelitsa · Baylor College Of Medicine · R01 · FY2024 · CA

CAR NKT Cell Immunotherapy of Neuroblastoma

$367,144
Leonid S Metelitsa · Baylor College Of Medicine · R01 · FY2025 · CA

CAR NKT Cell Immunotherapy of Neuroblastoma

$367,144
Leonid S Metelitsa · Baylor College Of Medicine · R01 · FY2023 · CA

CAR NKT Cell Immunotherapy of Neuroblastoma

$367,144
Leonid S Metelitsa · Baylor College Of Medicine · R01 · FY2021 · CA

Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy

$367,087
Drew M. Pardoll · Johns Hopkins University · R01 · FY2022 · CA

A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY

$367,087
Stephany Yi Tzeng · Johns Hopkins University · R37 · FY2023 · CA

Role of intratumoral high endothelial venules in tumor immunity

$367,087
Masanobu Komatsu · Johns Hopkins University · R01 · FY2023 · CA

Targeting Tumor Metabolism as a Means of Enhancing Immunotherapy

$367,087
Robert David Leone · Johns Hopkins University · R01 · FY2022 · CA